Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02281383 · ClinicalTrials.gov registry record · Phase 2
Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT02281383: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02281383 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02281383, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
This is a phase II study. This means that BCG therapy has already been found to be safe in humans. The investigators just want to see if using more treatments works better.
Interventions
- BIOLOGICAL Bacillus Calmette-Guérin (BCG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2014-10 |
| Est. Completion | 2022-02-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02281383
The ClinicalTrials.gov registry entry for NCT02281383 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bacillus Calmette-Guérin (BCG) is the first listed.
NCT02281383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02281383 about?
NCT02281383 is a clinical study titled "Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer". This is a phase II study. This means that BCG therapy has already been found to be safe in humans. The investigators just want to see if using more treatments works better.
What is the current status of trial NCT02281383?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2014-10. Estimated completion is 2022-02-24.
What interventions are being tested in trial NCT02281383?
The interventions under investigation include: Bacillus Calmette-Guérin (BCG) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02281383?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.